(+/-)-BPDZ 44 | 152382-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (+/-)-BPDZ 44
• 英文别名: 3-(1,2-DIMETHYLPROPYL)AMINO-4H-PYRIDO[4,3-e][1,2,4]THIADIAZINE 1,1-DIOXIDE；Bpdz 44；N-(3-methylbutan-2-yl)-1,1-dioxo-4H-pyrido[4,3-e][1,2,4]thiadiazin-3-imine
• CAS: 152382-67-7
• 化学式: C₁₁H₁₆N₄O₂S
• 分子量: 268.34
• InChiKey: XWCFBKQZEWEFOD-UHFFFAOYSA-N

物化性质

• 沸点：
  438.1±37.0 °C(Predicted)
• 密度：
  1.41±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  91.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2H-吡啶并[4,3-e][1,2,4]噻二嗪-3(4H)-酮1,1-二氧化物 在 盐酸 、 硫酸二甲酯 作用下， 以 吡啶 、 sodium hydroxide 、 水 、 碳酸氢钠 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 1,2-甲基丙胺 为溶剂， 生成 (+/-)-BPDZ 44
  参考文献：
  名称：

  Pyridothiadiazines

  摘要：

  该发明涉及一种选择自式(I)的化合物：##STR1##其中A、R.sub.1、R.sub.2和R.sub.4如描述中所定义，并且包含该化合物的药物产品，用于治疗与谷氨酸能神经传递功能障碍相关的病理。

  公开号：

  US05459138A1

文献信息

• Pyridothiadiazines
  申请人：Adir et Compagnie

  公开号：US05459138A1

  公开（公告）日：1995-10-17

  The invention relates to a compound selected from those of formula (I): ##STR1## in which A, R.sub.1, R.sub.2 and R.sub.4 are as defined in the description, and medicinal products containing the same which is useful for treating a pathology related to dysfunctioning of glutamatergic neurotransmission.

  该发明涉及一种选择自式(I)的化合物：##STR1##其中A、R.sub.1、R.sub.2和R.sub.4如描述中所定义，并且包含该化合物的药物产品，用于治疗与谷氨酸能神经传递功能障碍相关的病理。
• Therapeutic agents targeting the NCCA-ATP channel and methods of use thereof
  申请人：University of Maryland, Baltimore

  公开号：EP2359832A2

  公开（公告）日：2011-08-24

  The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, agonists and antagonists of the NCCA-ATP channel are contemplated. The therapeutic compositions are used to treat cancer, more specifically, a metastatic brain tumor, wherein a tumor-brain barrier is present. Such treatments are contemplated in combination with conventional anti-cancer therapies. Alternatively, the compositions are used to prevent cell death and to treat cerebral edema that result from ischemia, due to interruption of blood flow, to tissue trauma or to increased tissue pressure.

  本发明涉及针对星形胶质细胞、神经元或毛细血管内皮细胞的 NCCa-ATP 通道的治疗组合物及其使用方法。更具体地说，考虑使用 NCCA-ATP 通道的激动剂和拮抗剂。治疗组合物用于治疗癌症，更具体地说，治疗存在肿瘤-脑屏障的转移性脑肿瘤。这种治疗可考虑与传统的抗癌疗法相结合。另外，组合物还可用于防止细胞死亡和治疗因血流中断、组织创伤或组织压力增加而导致的缺血性脑水肿。
• Therapeutic methods that target the NCCA-ATP channel
  申请人：Simard J. Marc

  公开号：US10583094B2

  公开（公告）日：2020-03-10

  The present invention is directed to therapeutic compositions targeting the NCCa-ATP channel of an astrocyte, neuron or capillary endothelial cell and methods of using same. More specifically, agonists and antagonists of the NCCa-ATP channel are contemplated. The therapeutic compositions are used to treat cancer, more specifically, a metastatic brain tumor, wherein a tumor-brain barrier is present. Such treatments are contemplated in combination with conventional anti-cancer therapies. Alternatively, the compositions are used to prevent cell death and to treat cerebral edema that result from ischemia, due to interruption of blood flow, to tissue trauma or to increased tissue pressure.

  本发明涉及针对星形胶质细胞、神经元或毛细血管内皮细胞的 NCCa-ATP 通道的治疗组合物及其使用方法。更具体地说，考虑使用 NCCa-ATP 通道的激动剂和拮抗剂。治疗组合物用于治疗癌症，更具体地说，治疗存在肿瘤-脑屏障的转移性脑肿瘤。这种治疗可考虑与传统的抗癌疗法相结合。另外，组合物还可用于防止细胞死亡和治疗因血流中断、组织创伤或组织压力增加而导致的缺血性脑水肿。
• Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
  申请人：Stephenson T. Diane

  公开号：US20050009733A1

  公开（公告）日：2005-01-13

  The present invention provides compositions and methods for the treatment of central nervous system damage in a subject. More particularly, the invention provides a combination therapy for the treatment of a central nervous system ischemic condition or a central nervous system traumatic injury comprising the administration to a subject of a potassium ion channel modulator in combination with a cyclooxygenase-2 selective inhibitor.

  本发明提供了治疗受试者中枢神经系统损伤的组合物和方法。更具体地说，本发明提供了一种用于治疗中枢神经系统缺血性疾病或中枢神经系统创伤性损伤的组合疗法，包括向受试者施用钾离子通道调节剂与环氧合酶-2 选择性抑制剂。
• THERAPEUTIC AGENTS TRAGETING THE NCCA-ATP CHANNEL AND METHODS OF USE THEREOF
  申请人：University of Maryland, Baltimore

  公开号：EP1802313A2

  公开（公告）日：2007-07-04